


ICHOM Standard Set for

LOCALIZED PROSTATE CANCER

Treatment approaches covered

Watchful waiting | Active surveillance | Prostatectomy | External beam radiation therapy | Brachytherapy | Androgen Deprivation Treatment | Focal therapy | Other

For a complete overview of the ICHOM Standard Set, including definitions for each measure, time points for collection, and associated risk factors, visit ichom.org/medical-conditions/Localized-Prostate-Cancer



Details

- ¹ Recorded via the Clavien-Dindo-Classification
- ² Recorded via the Common Terminology Criteria for Adverse Events (CTCAE), version 4.0
- ³ Recommended to track via the Expanded Prostate Cancer Index Composite (EPIC 26 version preferred)



LOCALIZED PROSTATE CANCER


Revised: April 20th, 2015

CONTRIBUTORS

For more information about the process of developing a Standard Set, visit ichom.org/how-we-work/

The Sponsor

The Working Group



Australia

Kim Moretti | South Australian Prostate Cancer Clinical Outcomes Collaborative (SA-PCCOC); The Queen Elizabeth Hospital

Mark Frydenberg | Prostate Cancer Registry of Victoria; Monash University

Ian Roos* | Melbourne Graduate School of Education, University of Melbourne; Cancer Action Victoria

Germany

Hartwig Huland & Markus Graefen | Martini-Klinik at University Medical Center Hamburg-Eppendorf

Michael Froehner | University Hospital Carl Gustav Carus, Technical University of Dresden

Günter Feick* | Bundesverband Prostatakrebs Selbsthilfe (BPS); Europa UOMO

Thomas Wiegel | University Hospital Ulm

Ireland

Frank Sullivan | Galway University Hospital; Prostate Cancer Institute at NUI Galway

John Fitzpatrick | Irish Cancer Society

Israel

Jacob Ramon | Sheba Medical Center

Italy

Alberto Briganti | Vita-Salute San Raffaele University Hospital

Netherlands

Chris Bangma | Erasmus Medical Center

Sweden

Anna Bill-Axelsson | Uppsala University Hospital; National Prostate Cancer Register (NPCR) of Sweden

United Kingdom

Adam Glaser | Leeds Teaching Hospitals NHS Trust

James Catto | Academic Urology Unit and Academic Unit of Molecular Oncology, CR-UK/YCR Sheffield Cancer Research Centre

United States

Steven Jay Frank | MD Anderson Cancer Center

David Swanson | MD Anderson Cancer Center

Andrew Vickers | Memorial Sloan-Kettering Cancer Center

Adam Kibel | Dana-Farber Cancer Institute; Brigham and Women's Hospital

Anthony D'Amico | Dana-Farber Cancer Institute; Brigham and Women's Hospital

Neil Martin | Dana-Farber Cancer Institute; Brigham and Women's Hospital

Michael Blute | Massachusetts General Hospital

Howard Sandler | Cedars-Sinai Medical Center

Nancy Mendenhall | University of Florida Proton Therapy Institute

Ronald Chen | University of North Carolina Lineberger Comprehensive Cancer Center

Daniel Hamstra | University of Michigan Health System

Ashutosh Tewari | Icahn School of Medicine at Mount Sinai Hospital

*Patient representative